|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.05 EUR | -1.53% |
|
-8.94% | +10.14% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,092 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 6.63% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,599 | 1,721 | 1,818 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 14.46% | 7.64% | 5.65% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.3x | -9.9x | -12.7x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 3.97x | 4.45x | 4.98x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.6x | 0.6x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.67x | 3.52x | 2.78x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.57x | 2.89x | 2.42x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -6.49x | -10.5x | -23.7x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.13x | -9.78x | -19.9x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.09x | -14.9x | -25.9x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -11% | -6.73% | -3.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.244 | -1.88 | -1.464 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 447.6 | 594.6 | 751.5 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -246.2 | -163.3 | -76.84 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -260.9 | -175.9 | -91.43 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -244.1 | -158.9 | -136.3 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -493.5 | -371.4 | -274.2 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 18.62 | 18.62 | 18.62 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 01/03/22 | 01/03/23 | 27/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.39x | 3.96x | 10.22x | 0.56% | 70.73B | |
| 26.81x | 5.55x | 16.3x | 0.59% | 54.27B | |
| 37.72x | 12.9x | 24.55x | -.--% | 49.28B | |
| -44.25x | 3.17x | 9.36x | 3.41% | 39.94B | |
| 25.48x | 3.48x | 11.99x | -.--% | 30.36B | |
| 61.3x | 3.69x | 34.6x | -.--% | 25.96B | |
| -6.44x | 8.96x | -5.51x | -.--% | 22.14B | |
| 64.91x | 6.37x | 43.87x | -.--% | 19.96B | |
| -38.46x | 18.32x | -50.14x | -.--% | 16.77B | |
| Average | 16.16x | 7.38x | 10.58x | 0.51% | 36.6B | |
| Weighted average by Cap. | 17.36x | 6.61x | 13.25x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
